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Abstract 20 
Objective: Induction of labour at 39 weeks for nulliparous women aged 35 years and over 21 
may prevent stillbirths and does not increase caesarean births, so it may be popular. But the 22 
overall costs and benefits of such a policy have not been compared. 23 
Design: A cost-utility analysis alongside a randomised controlled trial (the 35/39 trial). 24 
Setting: Obstetric departments of 38 UK National Health Service hospitals and one UK 25 
primary care trust. 26 
Population: Nulliparous women aged 35 years or over on their expected due date, with a 27 
singleton live fetus in a cephalic presentation. 28 
Methods: Costs were estimated from the National Health Service and Personal Social 29 
Services perspective and quality-adjusted life years (QALYs) were calculated based on 30 
patient responses to the EQ-5D at baseline and four weeks. 31 
Main outcome measures: Data on antenatal care, mode of delivery, analgesia in labour, 32 
method of induction, EQ-5D (baseline and 4 weeks postnatal) and participant administered 33 
postnatal health resource use data was collected. 34 
Results: The intervention was associated with a mean cost saving of £263 and a small 35 
additional gain in QALYs (though not statistically significant), even without considering any 36 
possible QALY gains from stillbirth prevention.   37 
Conclusion: A policy of induction of labour at 39 weeks for women of advanced maternal 38 
age would save money. 39 
Trial registration: ISRCTN11517275. 40 
Keywords Cost-effectiveness, cost-utility, expectant management, induction of labour, 41 
nulliparous, advanced maternal age 42 
Tweetable abstract:  A policy of induction of labour at 39 weeks for women of advanced 43 
maternal age would save money. 44 
Introduction  45 
 46 
The age of childbearing is rising in women living in industrialised nations.  Women aged 35 47 
years or over have an increased risk of antepartum stillbirth at term. Induction is currently 48 
offered to all women in the UK at 41-42 weeks gestation, when the stillbirth risk is 2 to 3 in 49 
1000 (1, 2); older women experience this risk at earlier gestational ages (2.6 in 1000 from 37 50 
weeks onwards) (3).  Labour induction would likely reduce stillbirth, but may also increase 51 
caesarean delivery, already high for older women. Although randomised trials of induction 52 
for clinical problems near term have not shown an increase in caesarean, no randomised 53 
trial of induction based on age had been performed.   54 
  55 
The three commonest forms of economic evaluation in health-care are: cost-effectiveness, 56 
cost-utility and cost-benefit analyses (4).  Uniquely, a cost-utility analysis (CUA) measures 57 
outcomes in Quality Adjusted Life Years (QALYs).  QALYs can be applied across diseases and 58 
specialities allowing policy makers to judge which technologies should be funded (5). 59 
 60 
Increasingly economic outcomes for obstetric trials of ‘deliver or delay’ for various 61 
indications are reported.  The authors of HYPITAT reported a €831 saving associated with 62 
induction (6).  DIGITAT reported an additional cost of €111 in the induction group (7).  63 
PPROMEXIL reported a €754 additional cost associated with induction (8).  To our 64 
knowledge, no cost-utility analyses of an obstetric trial of ‘deliver or delay’ have been 65 
performed.   66 
 67 
A multi-centre, randomised [1:1] controlled trial of induction of labour between 390/7 and 68 
396/7 weeks gestation or expectant management  in 619 nulliparous pregnant women over 69 
35 years of age was performed (ISRCTN11517275).  Full clinical results are reported 70 
elsewhere (9).   71 
In an intention to treat analysis, there were no significant differences between groups in the 72 
proportion of women who had caesarean section (98 (32%) in the induction group versus 73 
103 (33%) in the expectant group (relative risk [RR] 0.99, 95% CI 0.87 – 1.14), or 74 
instrumental vaginal delivery (115 (38%) v. 104 (33%), respectively, RR 1.30, 95% CI 0.96 – 75 
1.77).  There were no maternal or infant deaths and no significant differences in maternal 76 
experience or adverse maternal or neonatal outcomes. Readmissions (of women) were 77 
higher in the control group.    The objective of this study was to perform a cost-utility 78 
analysis alongside the clinical trial. 79 
 80 
 81 
 82 
Methods 83 
 84 
Trial design 85 
 86 
Full details of the 35/39 trial methodology were reported previously (10).  Nulliparous 87 
women aged 35 years and over on their expected due date, with a singleton live fetus in a 88 
cephalic presentation were offered trial entry.  Women were randomised at 36+0 – 39+6 89 
weeks gestation.   90 
 91 
Intervention 92 
 93 
Women were randomly allocated to either induction of labour between 39+0 and 39+6 weeks 94 
gestation, or to expectant management i.e. awaiting spontaneous onset of labour unless a 95 
situation developed necessitating delivery either by induction or caesarean.  Women 96 
randomised to the expectant management group were offered induction between 41+0 and 97 
42+0 (i.e. 7-14 days after the due date), with the exact time determined by their preference 98 
and the consultant’s usual practice.   In all cases where women underwent induction of 99 
labour, this was carried out on an inpatient basis. 100 
   101 
Outcome measures 102 
 103 
The primary outcome was caesarean delivery and secondary outcomes include instrumental 104 
vaginal delivery, intrapartum and postpartum morbidity (need for blood transfusion, 105 
systemic infection).  The neonatal secondary outcomes were livebirth/stillbirth, birth 106 
weight, neonatal intensive care admission, birth trauma and two composite outcomes for 107 
serious neonatal morbidity (direct trauma and hypoxic trauma).  108 
 109 
Other secondary outcomes included maternal delivery expectation/experience measured by 110 
the Childbirth Experience Questionnaire (11) sent at one month postnatal. 111 
 112 
Health outcomes 113 
 114 
Health-related quality of life (HRQL) was measured at the time of randomisation and one 115 
month post-delivery using the EuroQol EQ-5D-5L measure; responses were used to generate 116 
quality-adjusted life-years (QALYs).  117 
 118 
The EQ-5D-5L was launched in 2009 (12) and consisted of 5 levels of response instead of 3 119 
levels as was the case with its predecessor the EQ-5D-3L.  A valuation set is currently being 120 
developed for the UK for the EQ-5D-5L.  At present ‘crosswalk’ value sets exist for the EQ-121 
5D-5L whereby values obtained by using the EQ-5D-5L can be used to obtain utility weights 122 
for the EQ-5D-3L.   A detailed methodology for this is provided in the literature (12). 123 
 124 
Collection and valuation of resource use data 125 
 126 
Resource utilisation was captured through two sources: firstly routine health service data 127 
collection systems; and secondly patient questionnaires administered at one month 128 
postnatal.  Full resource use data was collected for all participants from 11th November 129 
2013 (participant number 215 onwards) from the hospital notes at discharge by the 130 
research midwife or nurse at the participating centre.  Prior to 11th November 2013 131 
incomplete data on resource use was collected for the first 215 participants.  From 11th 132 
November 2013 all participants received a Health Resource Use Questionnaire at one month 133 
postnatal to capture resource use after hospital discharge.  Data on resource use after 134 
hospital discharge was not collected for the first 215 participants. 135 
 136 
The economic assessment method as far as possible adhered to the recommendations of 137 
the NICE Reference Case(13).  Primary research methods were followed to estimate the 138 
costs of the treatment options, including drugs and rehabilitation inputs. 139 
 140 
Unit costs for health and social care resources were derived from local and national sources 141 
and estimated in line with best practice (14-18). Primary research using established 142 
accounting methods were also required to estimate unit costs. Costs were standardised to 143 
current prices where possible.  Units costs fell into 5 main groups: staff, procedure related, 144 
investigations, admissions and drugs (used for the process of induction of labour/analgesia 145 
in labour/other).  Unit costs of health and social care resource items are shown in Tables S1. 146 
 147 
Cost Effectiveness Analysis  148 
 149 
A prospective economic evaluation, conducted from a NHS and personal social services 150 
(PSS) perspective, was integrated into the trial design. The economic evaluation estimated 151 
the difference in the cost of resource inputs used by participants in the two arms of the trial, 152 
allowing comparisons to be made between the two  treatment options (induction of labour 153 
versus expectant management) for nulliparous women over 35 years of age and enabling 154 
costs and consequences to be compared.   155 
Cost-utility analysis assesses two alternative courses of action in terms of their cost and 156 
outcome expressed in QALYs.  The comparison is expressed using the Incremental Cost 157 
Effectiveness Ratio (ICER).  The ICER is a measure of the additional cost per additional unit of 158 
health gain produced by one course of action compared to another, i.e. the cost per QALY 159 
gained.  The cost effectiveness threshold is described as what society is willing to pay for an 160 
additional unit of health gain (QALY).  The threshold currently set by NICE is £20,000 - 161 
£30,000 (13). We also presented the results in terms of Incremental Net Benefit (INB) 162 
statistics, calculated by multiplying the incremental effects by an assumed monetary value 163 
of a QALY (the cost effectiveness threshold) and subtracting the incremental cost. We 164 
calculated INB statistics based on £10,000 to £50,000 per QALY. A positive INB suggests that 165 
the intervention is cost-effective compared with usual care at the defined threshold. 166 
Decision uncertainty was addressed by constructing cost-effectiveness acceptability curves 167 
across cost-effectiveness threshold values of between £0 and £100,000 for the outcomes of 168 
interest. If the figure is greater than 0.5, it indicates that the intervention is more likely to be 169 
cost-effective than not. 170 
 171 
Using an intention to treat approach, costs and outcomes for each trial participant were 172 
calculated.  The costs and outcomes for the two groups were analysed using Stata Version 173 
13.   Non-parametric bootstrap estimation was used to derive 95% confidence intervals for 174 
mean cost differences between the trial groups.  175 
 176 
The base case assumption was that induction neither prevented nor caused stillbirth. We 177 
performed a sensitivity analysis to measure the cost effectiveness of induction for a range of 178 
stillbirth rate prevented/caused.  179 
 180 
Non-parametric estimation is required as health care costs are typically positively skewed 181 
i.e. a small number of patients will incur very high costs.  Bootstrap estimation allows a 182 
statistic of interest (such as the mean) to be calculated from samples which are not normally 183 
distributed, or indeed samples where the distribution is unknown.  Our results were based 184 
on 1000 bootstrap samples, which was sufficient to provide estimated costs and effects. 185 
 186 
Results  187 
 188 
Full resource use data at hospital discharge was collected from the hospital records for 380 189 
(61%) trial participants from 11th February 2013 onwards (participants 239 – 619).  Data on 190 
antenatal care, mode of delivery, analgesia required in labour, method of induction of 191 
labour used was available for all 619 participants.  Of the 380 trial participants for whom 192 
economic outcomes were collected: EQ-5D at baseline was available for 349 (92%) 193 
participants;  EQ-5D at 4 weeks postnatal was available for 277 (73%) participants; health 194 
resource use after hospital discharge data was available for 297 (78%) participants.  The 195 
economic analysis was performed on the data for 380 trial participants.  Relevant unit costs 196 
are presented in Table S1. 197 
 198 
There were two predominant differences in resource use between the induction of labour 199 
and expectant management groups (Table S2).  The first was a higher mean cost for assisted 200 
delivery in the induction group than the expectant group (mean cost 1006 vs. 888) which 201 
was offset by a lower mean cost for normal vaginal delivery in the induction group than the 202 
expectant group (mean cost 585 vs. 672).  The second was a higher mean cost for hospital 203 
readmission in the expectant group (due to three more readmissions) than the induction 204 
group (mean cost 383 vs. 128), this was the single highest mean difference in cost for an 205 
individual cost category between the two groups.   206 
 207 
Healthcare cost data tends to be highly skewed. This can only be partly addressed using 208 
parametric methods because the arithmetic mean is the informative instrument, providing 209 
information about the cost of treating all patients, which is required for healthcare policy 210 
decisions (19). In order to fully address the skewed nature of the data we performed 211 
additional non-parametric analyses on the cost differences between the two groups. 212 
Initially, we conducted a bootstrap (using 1,000 replications with resampling) of the mean 213 
cost differences for each cost category within this dataset, for women in the induction 214 
group and the expectant group (Table S2). 215 
 216 
These resource quantities were multiplied by the relevant unit costs (Table S1) to provide 217 
estimates of the means costs per patient (Table S2).  Differences between the groups in the 218 
cost of healthcare use show a mean cost saving of £263 (95% confidence interval [CI] (-£646 219 
to £174) using non-parametric bootstrap estimation) associated with induction of labour, 220 
though there was a wide confidence interval around this estimate.  This difference was 221 
largely attributable to the higher mean cost of readmissions in the expectant group than the 222 
induction group. 223 
 224 
Mean EQ-5D utility scores for women in the induction of labour group and expectant 225 
management group at baseline and at 4 weeks postnatal were used to calculate the mean 226 
QALYs gained in each group.  The mean QALYs gained over the trial period based on EQ-5D 227 
utility measure were slightly higher for the  induction of labour group  than the expectant 228 
management group (0.03  versus 0.01) (Table 1) although this was not statistically 229 
significant. 230 
 231 
The results of the incremental cost-effectiveness analysis of the induction of labour group 232 
compared with expectant management group are presented in Table 2. ICER was calculated 233 
using differences in costs divided by differences in effects between induction of labour and 234 
using the expectant management group as the reference group. As the intervention 235 
(induction of labour) is associated with a gain in QALYs and a lower mean cost than the 236 
expectant management group this results in a negative ICER (-£114,526) , reflecting both 237 
cost-savings and positive QALYs. The differences in effects are very small; however these are 238 
magnified in the ICER calculations, as the mean differences in effects are used as the 239 
denominators of the ICER statistics. These estimates have very wide confidence intervals. 240 
One thousand bootstrapped weighted estimates for each of the ICERs are presented on 241 
cost-effectiveness planes (Figure 2). 242 
 243 
A weighted bootstrapped scatterplot is represented graphically in cost-effectiveness planes 244 
in Figure 1. The origin of the cost-effectiveness plane represents the average cost and 245 
average effect for the reference group, in this case expectant management. The point 246 
estimate of mean ICER therefore represents the incremental changes in costs and effects 247 
generated by the differences between the induction of labour and expectant group. In each 248 
analysis, 1,000 bootstrapped mean ICERs were plotted on the cost effectiveness plane. They 249 
show the uncertainty around the mean reported ICERs.  250 
 251 
Cost-effectiveness acceptability curves (CEACs) were generated to show the probability of 252 
the induction of labour planning being optimal in terms of cost-effectiveness at alternative 253 
cost-effectiveness thresholds held by decision-makers. Cost-effectiveness thresholds were 254 
varied from £10,000 to £50,000, with £20 000 considered to be the most intuitive threshold 255 
for the QALYs.  Induction of labour plan has a 100% probability of being cost effective 256 
comparing to the expectant management plan in nulliparous pregnant women over 35 years 257 
age across all cost-effectiveness thresholds. 258 
 259 
 260 
Discussion 261 
 262 
Main findings 263 
 264 
Induction of labour at 39 weeks for women of advanced maternal age is associated with a 265 
small gain in QALYs and is cheaper by £263 on average than expectant management.  The 266 
difference in cost between the two arms of the study predominantly arose due to an 267 
increase in postnatal readmissions to hospital (three more) in the expectant management 268 
arm of the study. 269 
 270 
Strengths and limitations 271 
 272 
The use of a prospective randomised trial design provided unbiased and comprehensive 273 
data to perform a cost-utility analysis.  Unfortunately complete health resource use data 274 
was only captured from November 2013 onwards.  This means the cost utility analysis could 275 
only be performed for 380 (61%) participants.  276 
 277 
 There has been a recent increase in reporting of economic outcomes for obstetric trials of 278 
‘deliver or delay’ for various indications with some reporting a cost saving associated with 279 
induction (6) and others a cost incurred (7, 8) .  Previous economic evaluations have taken 280 
the form of cost-effectiveness analyses.  This is the first cost-utility analysis of an obstetric 281 
trial of ‘deliver or delay’.  Allowing the outcomes to be measured in QALYs means the value 282 
of the intervention can be considered in a broader context by policy makers.  Previous 283 
economic evaluations have collected data on resource use until hospital discharge (DIGITAT, 284 
PPROMEXIL) and will therefore have missed costs incurred in the postnatal period which 285 
had a big impact on the results of our study. 286 
 287 
The limited time horizon of the study meant that the follow up of outcomes were limited to 288 
up to 4 week-postnatal care. It is frequently observed that morbidities associated with 289 
labour and birth and its management affect women and babies in the long run. Follow up 290 
over weeks or longer to monitor recovery, or a future assessment of the outcomes for 291 
mothers and babies at a later date, would shed more light on long term cost-effectiveness.   292 
 293 
The analysis presented here assumes that induction neither prevents nor causes stillbirth.  If 294 
plausibly we assume that induction prevents say half of all antepartum stillbirths from 39 295 
weeks onwards in this group of women, and an absolute rate of 1 in 500 for such stillbirths 296 
beyond 39 weeks, then a policy of induction should result in 1 in 1000 women having a 297 
stillbirth prevented.  If stillbirth is associated with a loss of 25 QALYs (20), then the 298 
prevention of 1 in 1000 women having a stillbirth would result in the addition of  25 QALYs 299 
per 1000 women or 0.025 QALY per woman.  This hypothetical, but plausible gain is ten 300 
times larger than the net increase in QALY per woman from other aspects of care. Its 301 
inclusion would result in an even more cost effective intervention. 302 
While the cost of the induction may not be higher than expectant management, the authors 303 
acknowledge that were induction to be offered to all women of advanced maternal age this 304 
would have an impact on the already stretched working capacity of maternity units.  305 
Interpretation 306 
 307 
Induction of labour at 39 weeks for women of advanced maternal age has no adverse 308 
effects on short term maternal or neonatal outcomes, in particular it does not increase 309 
caesareans.  It therefore appears safe to be tested as a strategy to prevent late antepartum 310 
stillbirths in this group of women.  This cost-utility analysis has shown that should such a 311 
strategy be adopted it would likely save money even without preventing stillbirths. 312 
 313 
 314 
Conclusion 315 
 316 
This cost-utility analysis has shown that a policy of induction of labour at 39 weeks for 317 
women of advanced maternal age would probably save money even if it did not prevent 318 
stillbirths.  319 
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